NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Obtains Patent for Use of CLR 124 in PET Imaging
Cellectar Biosciences (NASDAQ: CLRB) this morning said the United States Patent and Trademark Office has granted a method of use patent for CLR 124, the cancer imaging agent that utilizes the company’s proprietary phospholipid drug conjugate (PDC) delivery platform. The newly issued patent, titled “Phospholipid Ether Analogs as Agents for Detecting and Locating Cancer and Methods Thereof,” provides intellectual property protection through March 2, 2025. The patent outlines the use of CLR 124 in PET imaging to detect radiation-insensitive or chemotherapy-insensitive cancers and cancer metastases. Additionally, the patent provides coverage for the use of CLR 124 in identifying the location…







